Verona Pharma PLC ADR VRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $15.59
- Day Range
- $15.16–15.95
- 52-Week Range
- $11.83–23.81
- Bid/Ask
- $15.21 / $15.98
- Market Cap
- $1.18 Bil
- Volume/Avg
- 316,407 / 446,571
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 79
- Website
- https://www.veronapharma.com
Valuation
Metric
|
VRNA
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.03 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
VRNA
Financial Strength
Metric
|
VRNA
|
---|---|
Quick Ratio | 32.53 |
Current Ratio | 33.33 |
Interest Coverage | −31.40 |
Quick Ratio
VRNA
Profitability
Metric
|
VRNA
|
---|---|
Return on Assets (Normalized) | −13.61% |
Return on Equity (Normalized) | −15.65% |
Return on Invested Capital (Normalized) | −17.35% |
Return on Assets
VRNA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nqtdrmnmhg | Ddxy | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zxpcmsnbw | Kvcvlm | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nbtgmtp | Sppfsyc | $99.5 Bil | |
MRNA
| Moderna Inc | Tnjwjvyz | Zxf | $38.8 Bil | |
ARGX
| argenx SE ADR | Sgpzhdsv | Ffmsv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Cbkcxpdx | Zxq | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zsrlcsth | Xhshlt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tvvjvpztq | Cdvkcq | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bxyqpvpnp | Clnyr | $12.4 Bil | |
INCY
| Incyte Corp | Wjdhcfrdp | Pycpgj | $11.9 Bil |